S16 - MS Characterizations and Tools for Measurement

Event Time: Monday April 24, 2017 3:30 pm to 5:30 pm
Topic(s): MS and CNS Inflammatory Disease
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
3:30 PM 001 Genetic descriptors of a multiple sclerosis cohort Noriko Isobe, MD
Disclosure:
Dr. Isobe has nothing to disclose.

3:42 PM 002 A Global Epidemiological Forecast of Multiple Sclerosis and Disease Subtypes Sunali Goonesekera
Disclosure:
Dr. Goonesekera has received personal compensation for activities with Decision Resources Group as an employee.

3:54 PM 003 Progressive degeneration of RNFL and GCL is seen in pediatric MS in comparison to monophasic demyelination and controls Giulia Longoni, MD
Disclosure:
Dr. Longoni has nothing to disclose.

4:06 PM 004 Sample sizes and clinical relevance of MS-specific atrophy markers: A comprehensive, unbiased, simulation-based method accounting for normal aging Christina Azevedo, MD
Disclosure:
Dr. Azevedo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi-Genzyme, Genentech, Novartis, Hoffman-LaRoche.

4:18 PM 005 Ofatumumab versus teriflunomide in relapsing MS: adaptive design of two Phase 3 studies (ASCLEPIOS I and ASCLEPIOS II) Stephen L Hauser, MD
Disclosure:
Dr. Hauser has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Symbiotix, Annexon, Bionure, Molecular Stethoscope. Dr. Hauser has received compensation for serving on the Board of Directors of Neurona.

4:30 PM 006 Microstructural Deterioration in Multiple Sclerosis Patients Meeting Criteria for “no evidence of disease activity”: Correlations with Clinical Variables Dylan Sperling
Disclosure:
Dr. Sperling has nothing to disclose.

4:42 PM 007 Upper Cervical Cord Area Atrophy for Clinical Trials in Multiple Sclerosis Esha Datta
Disclosure:
Dr. Datta has nothing to disclose.

4:54 PM 008 Circulating microRNAs are associated with acute inflammation in patients with multiple sclerosis. Maria Antonietta Mazzola, MD
Disclosure:
Dr. Mazzola has nothing to disclose.

Register Now

Related Courses